FILINGS
AZN 0000901832 | |||
---|---|---|---|
Filing Date | Form Type | Description | Document |
2021-04-14 | 6-K | TAGRISSO APPROVED IN CHINA IN EARLY LUNG CANCER | View Document |
2021-04-13 | 424B3 | 424B3 | View Document |
2021-04-12 | EFFECT | View Document | |
2021-04-12 | 425 | 425 | View Document |
2021-04-12 | 6-K | FORM 6-K | View Document |
2021-04-12 | 6-K | CIRCULAR AND NOTICE OF GENERAL MEETING | View Document |
2021-04-12 | 425 | 425 | View Document |
2021-04-12 | 6-K | UPDATE ON FARXIGA COVID-19 DARE-19 PHASE III TRIAL | View Document |
2021-04-09 | F-4/A | F-4/A | View Document |
2021-04-08 | CORRESP | View Document | |
2021-04-08 | SC 13G | SC 13G | View Document |
2021-04-01 | 425 | 425 | View Document |
2021-04-01 | 425 | 425 | View Document |
2021-04-01 | 425 | 425 | View Document |
2021-04-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
2021-03-30 | 6-K | NOTICE OF AGM | View Document |
2021-03-30 | 6-K | FORM 6-K | View Document |
2021-03-25 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
2021-03-25 | 6-K | AZD1222 US PH3 PRIMARY ANALYSIS CONFIRMS EFFICACY | View Document |
2021-03-22 | 6-K | ASTRAZENECA US VACCINE TRIAL MET PRIMARY ENDPOINT | View Document |
2021-03-16 | 4 | 4 | View Document |
2021-03-16 | 6-K | DIVESTMENT OF VIELA SHAREHOLDING COMPLETED | View Document |
2021-03-16 | 6-K | US SUPPLY AGREEMENT FOR ADDITIONAL AZD7442 DOSES | View Document |
2021-03-12 | 425 | 425 | View Document |
2021-03-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
2021-03-04 | 6-K | DESIGNATION OF EU HOME MEMBER STATE FOR EU SECURITIES REGULATION PURPOSES | View Document |
2021-03-03 | 6-K | US COURT DECISION FAVOURS SYMBICORT PATENTS | View Document |
2021-03-02 | 6-K | FURTHER UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNE | View Document |
2021-03-01 | UPLOAD | View Document | |
2021-03-01 | 6-K | TRANSPARENCY DIRECTIVE VOTING RIGHTS AND CAPITAL | View Document |
2021-02-26 | 425 | 425 | View Document |
2021-02-25 | 425 | 425 | View Document |
2021-02-22 | 6-K | VOLUNTARY WITHDRAWAL OF IMFINZI INDICATION IN ADVANCED BLADDER CANCER IN THE US | View Document |
2021-02-19 | F-4 | F-4 | View Document |
2021-02-17 | 6-K | LYNPARZA: IDMC RECOMMEND EARLY ANALYSIS OF OLYMPIA | View Document |
2021-02-16 | IRANNOTICE | IRANNOTICE | View Document |
2021-02-16 | 6-K | FILING OF FORM 20-F WITH SEC | View Document |
2021-02-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
2021-02-16 | 6-K | ANNUAL FINANCIAL REPORT | View Document |
2021-02-16 | 20-F | 20-F | View Document |
2021-02-12 | 425 | 425 | View Document |
2021-02-11 | 425 | 425 | View Document |
2021-02-11 | 425 | 425 | View Document |
2021-02-11 | 425 | 425 | View Document |
2021-02-11 | 425 | 425 | View Document |
2021-02-11 | 6-K | ASTRAZENECA NON-EXECUTIVE BOARD CHANGES | View Document |
2021-02-11 | 6-K | AZN: FULL-YEAR 2020 RESULTS | View Document |
2021-02-10 | SC 13G | SC 13G | View Document |
2021-02-10 | SC 13G/A | SC 13G/A | View Document |
2021-02-10 | 6-K | DIVESTMENT OF CRESTOR IN EUROPE COMPLETED | View Document |
2021-02-05 | 6-K | UPDATE ON KESTREL PHASE III TRIAL FOR IMFINZI | View Document |
2021-02-04 | 6-K | FORXIGA APPROVED IN CHINA FOR HEART FAILURE | View Document |
2021-02-03 | SC 13G/A | SEC SCHEDULE 13G | View Document |
2021-02-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
2021-02-01 | 6-K | ASTRAZENECA AGREES TO DIVEST VIELA SHAREHOLDING | View Document |
2021-02-01 | 6-K | COVID-19 VACCINE AUTHORISED FOR USE BY THE EU | View Document |
2021-01-29 | 6-K | COVID-19 VACCINE RECEIVES POSITIVE OPINION IN EU | View Document |
2021-01-29 | SC 13G/A | View Document | |
2021-01-26 | 6-K | BLOCK LISTING APPLICATION | View Document |
2021-01-26 | 6-K | SYMBICORT APPROVED IN CHINA FOR MILD ASTHMA | View Document |
2021-01-25 | 6-K | CALQUENCE APPROVED IN JAPAN FOR CLL | View Document |
2021-01-25 | 6-K | CALQUENCE MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB | View Document |
2021-01-20 | 6-K | ENHERTU APPROVED IN THE EU FOR BREAST CANCER | View Document |
2021-01-19 | 6-K | ENHERTU APPROVED IN THE US FOR GASTRIC CANCER | View Document |
2021-01-15 | 6-K | IMFINZI APPROVED IN THE EU FOR LESS-FREQUENT, FIXED- DOSE USE IN UNRESECTABLE NO | View Document |
2021-01-06 | 6-K | FARXIGA GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF PATIENTS WITH CHR | View Document |
2021-01-04 | 6-K | TOTAL VOTING RIGHTS | View Document |
2021-01-04 | 6-K | ATACAND DIVESTMENT TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES COMPLETED | View Document |
2020-12-30 | 6-K | ASTRAZENECA'S COVID-19 VACCINE AUTHORISED IN UK | View Document |
2020-12-29 | 6-K | LYNPARZA APPROVED IN JAPAN FOR THE TREATMENT OF ADVANCED OVARIAN, PROSTATE AND P | View Document |
2020-12-21 | 6-K | TAGRISSO APPROVED IN THE US FOR THE ADJUVANT TREATMENT OF PATIENTS WITH EARLY-ST | View Document |
2020-12-21 | 6-K | UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNEY DISEAS | View Document |
2020-12-18 | 425 | 425 | View Document |
2020-12-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
2020-12-17 | 425 | 425 | View Document |
2020-12-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
2020-12-15 | 425 | 425 | View Document |
2020-12-15 | 6-K | IMFINZI NEW DOSE RECEIVES POSITIVE EU CHMP OPINION | View Document |
2020-12-14 | 425 | 425 | View Document |
2020-12-14 | 425 | 425 | View Document |
2020-12-14 | 425 | 425 | View Document |
2020-12-14 | 425 | 425 | View Document |
2020-12-14 | 6-K | TRASTUZUMAB DERUXTECAN POSITIVE CHMP | View Document |
2020-12-14 | 6-K | TRIXEO AEROSPHERE APPROVED IN THE EU FOR COPD | View Document |
2020-12-14 | 6-K | ASTRAZENECA TO ACQUIRE ALEXION PHARMACEUTICALS INC | View Document |
2020-12-01 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
2020-12-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
2020-12-01 | 6-K | CRESTOR TO BE DIVESTED TO GRUNENTHAL IN EUROPE | View Document |
2020-11-30 | 6-K | FORXIGA APPROVED IN JAPAN FOR CHRONIC HEART FAILURE | View Document |
2020-11-23 | 6-K | AZD1222 VACCINE EFFECTIVE AGAINST COVID-19 | View Document |
2020-11-20 | 6-K | IMFINZI NEW DOSING APPROVED IN THE US | View Document |
2020-11-13 | 25-NSE | View Document | |
2020-11-10 | 6-K | TEZEPELUMAB PHASE III TRIAL MET PRIMARY ENDPOINT | View Document |
2020-11-09 | 6-K | CALQUENCE APPROVED IN THE EU FOR CLL | View Document |
2020-11-06 | 6-K | BRILINTA APPROVED IN THE US IN STROKE | View Document |
2020-11-05 | 6-K | AZN: YEAR-TO-DATE AND Q3 2020 RESULTS | View Document |
2020-11-05 | 6-K | FORXIGA APPROVED IN THE EU FOR HEART FAILURE | View Document |
2020-11-05 | 6-K | LYNPARZA APPROVED IN THE EU AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F | View Document |
2020-11-05 | 6-K | LYNPARZAAPPROVED IN THE EU FOR THE TREATMENT OF BRCA- MUTATED METASTATIC CASTRAT | View Document |
2020-11-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.